Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 55, 2020 - Issue 9
Submit an article Journal homepage
279
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience

Robert Mahna Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
,
Annabelle Vogta Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
,
Patrick Kupczyka Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
,
Farsaneh Sadeghlara Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
,
Katrin van Beekuma Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
,
Robert Hüneburga Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
,
Carsten Meyerb Department of Radiology, University Hospital Bonn, Bonn, GermanyView further author information
,
Marieta Tomac Department of Pathology, University Hospital Bonn, Bonn, GermanyView further author information
,
Hojjat Ahmadzadehfarc Department of Pathology, University Hospital Bonn, Bonn, Germany;d Nuclear Medicine Clinic, Dortmund, GermanyView further author information
,
Markus Esslere Department of Nuclear Medicine, University Hospital Bonn, Bonn, GermanyView further author information
,
Hanno Matthaeif Department of Visceral Surgery, University Hospital Bonn, Bonn, GermanyView further author information
,
Philipp Lingohrf Department of Visceral Surgery, University Hospital Bonn, Bonn, GermanyView further author information
,
Jörg C. Kalfff Department of Visceral Surgery, University Hospital Bonn, Bonn, GermanyView further author information
,
Christian P. Strassburga Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyView further author information
&
Maria A. Gonzalez-Carmonaa Department of Internal Medicine I, University Hospital Bonn, Bonn, GermanyCorrespondence[email protected]
View further author information
 show all
Pages 1057-1062 | Received 20 May 2020, Accepted 06 Jul 2020, Published online: 21 Jul 2020

References

  • Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
  • Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
  • Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
  • Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–319.
  • Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
  • El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.
  • Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952.
  • Finn RS, Ryoo BY, Merle P, KEYNOTE-240 investigators, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.
  • Yau T, Park JW, Finn RS, et al. CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC).LBA38_PR ESMO. 2019.
  • European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
  • Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–142.
  • Feng D, Hui X, Shi-Chun L, et al. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget. 2017;8(57):96649–96655.
  • Kambhampati S, Bauer KE, Bracci PM, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer. 2019;125(18):3234–3241.
  • Scheiner B, Kirstein MM, Hucke F, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49(10):1323–1333.
  • Finkelmeier F, Czauderna C, Perkhofer L, et al. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol. 2019;145(1):253–259.
  • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
  • Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
  • Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–1458.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.